# Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

> **NCT04010071** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Hepatobiliary Neoplasm
- Liver Neoplasm
- Biliary Tract Neoplasms

## Interventions

- **DRUG:** axitinib plus toripalimab

## Key facts

- **NCT ID:** NCT04010071
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04010071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04010071, "Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04010071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*